Casirivimab is part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. Casirivimab is a monoclonal antibody combined with Imdevimab in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19.
- Mechanism
- Curator reviewed · 3 references
Casirivimab is a recombinant human IgG1 monoclonal antibody targeting the receptor binding domain of the spike protein of SARS-CoV-2; a protein playing an important role in viral attachment, fusion, and entry into the cell. Together with imdevimab, casirivimab neutralizes the spike protein of SARS-CoV-2.
- Primary indication
- According to the Emergency Use Authorization (EUA) by the FDA and EMA, indevimab is used only with casirivimab to prevent COVID-19 and treat mild to moderate COVID-19 from laboratory-confirmed SARS-CoV-2 infection in patients aged 12...Curator reviewed
- First approval
- Canada, 2021 · European Union, 2021
- Code names
- REGN-10933
- Brand names
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with Casirivimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account